ArticleJournal of thoracic disease2025
Treatment outcomes and safety of concurrent chemoradiation in older adults with unresectable stage III non-small-cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Collagenous endobronchial obliteration after chemoradiation followed by consolidation osimertinib: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for patients with unresectable stage III non-small-cell lung cancer (NSCLC) and good performance status. However, there is no consensus regarding the treatment of older patients with stage III NSCLC. Therefore, this study aimed to investigate treatment outcomes and safety of CCRT in older patients with unresectable stage III NSCLC compared with those in younger patients. Methods: We retrospectively examined all patients with unresectable stage III NSCLC treated with CCRT between 2012 and 2023 at four Korean hospitals. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared between patients aged ≥70 years (older) and those aged <70 years (younger). We also analyzed data for age cutoffs of 60, 65, and 75 years. Results: Among 131 participants, 47 were classified as older patients and 84 as younger patients. Baseline characteristics, including Eastern Cooperative Oncology Group performance status and comorbidities, were mostly similar. In multivariable-adjusted models, older and younger patients had similar PFS [adjusted hazard ratio (aHR), 1.45; 95% confidence interval (CI): 0.85-2.48]; the median PFS in older and younger patients was 9.9 and 12.9 months, respectively (P=0.94). However, in multivariable-adjusted models, older patients had worse OS (aHR, 2.33; 95% CI: 1.27-4.27); the median OS in older and younger patients was 24.1 and 27.2 months, respectively (P=0.36). AEs of any grade and those of grade ≥3 were not significantly different between older and younger groups. Conclusions: Among patients with unresectable stage III NSCLC undergoing CCRT, older patients aged ≥70 years had similar PFS and AE rates compared with those aged <70 years. However, OS was worse in older patients. Considering age as a crucial factor in CCRT outcomes, efforts should be made to provide a more meticulous and careful approach for older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.